The treatment landscape for atopic dermatitis has undergone a transformation in the last seven years, spurred largely by the launch of Sanofi and Regeneron’s blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab) in 2017. Today, there are a range of topical, oral and biologic drugs and different mechanisms of action available to treat moderate-to-severe atopic dermatitis, but many patients continue to experience persistent itching and remain uncontrolled.
Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
More from Market Snapshot
• By
IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.
• By
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
• By
More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.
• By
KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.
More from Immunological
• By
The France-based giant inks a transaction potentially worth around $1.9bn to get hold of Dren Bio’s autoimmune disease treatment DR-0201.
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
In the crowded and competitive field of generalized myasthenia gravis, Amgen has faith that Uplizna’s twice-yearly administration will make it the treatment of choice.